These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38415822)

  • 1. Using forest plots to interpret covariate effects in pharmacometric models.
    Jonsson EN; Nyberg J
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):743-758. PubMed ID: 38415822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Covariate modeling in pharmacometrics: General points for consideration.
    Sanghavi K; Ribbing J; Rogers JA; Ahmed MA; Karlsson MO; Holford N; Chasseloup E; Ahamadi M; Kowalski KG; Cole S; Kerwash E; Wade JR; Liu C; Wang Y; Trame MN; Zhu H; Wilkins JJ;
    CPT Pharmacometrics Syst Pharmacol; 2024 May; 13(5):710-728. PubMed ID: 38566433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V
    Lommerse J; Plock N; Cheung SYA; Sachs JR
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1092-1106. PubMed ID: 34242494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scientific and regulatory evaluation of empirical pharmacometric models: An application of the risk informed credibility assessment framework.
    Skottheim Rusten I; Musuamba FT
    CPT Pharmacometrics Syst Pharmacol; 2021 Nov; 10(11):1281-1296. PubMed ID: 34514745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linked Pharmacometric-Pharmacoeconomic Modeling and Simulation in Clinical Drug Development.
    Hill-McManus D; Marshall S; Liu J; Willke RJ; Hughes DA
    Clin Pharmacol Ther; 2021 Jul; 110(1):49-63. PubMed ID: 32936931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covariates in Pharmacometric Repeated Time-to-Event Models: Old and New (Pre)Selection Tools.
    Goulooze SC; Krekels EHJ; Hankemeier T; Knibbe CAJ
    AAPS J; 2018 Dec; 21(1):11. PubMed ID: 30565031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.
    Zhu P; Sy SKB; Skerjanec A
    AAPS J; 2018 Mar; 20(2):40. PubMed ID: 29516330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Full random effects models (FREM): A practical usage guide.
    Jonsson EN; Nyberg J
    CPT Pharmacometrics Syst Pharmacol; 2024 Aug; 13(8):1297-1308. PubMed ID: 38937897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Operating characteristics of stepwise covariate selection in pharmacometric modeling.
    Ahamadi M; Largajolli A; Diderichsen PM; de Greef R; Kerbusch T; Witjes H; Chawla A; Davis CB; Gheyas F
    J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):273-285. PubMed ID: 31020450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confidence and Prediction Intervals for Pharmacometric Models.
    Kümmel A; Bonate PL; Dingemanse J; Krause A
    CPT Pharmacometrics Syst Pharmacol; 2018 Jun; 7(6):360-373. PubMed ID: 29388347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?
    Chasseloup E; Yngman G; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):485-492. PubMed ID: 32661654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of covariate effects using forest plots and introduction to the coveffectsplot R package.
    Marier JF; Teuscher N; Mouksassi MS
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1283-1293. PubMed ID: 35670230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants.
    An G
    Curr Pharmacol Rep; 2020 Oct; 6(5):260-266. PubMed ID: 33767946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
    Gieschke R; Steimer JL
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reporting guidelines for population pharmacokinetic analyses.
    Dykstra K; Mehrotra N; Tornøe CW; Kastrissios H; Patel B; Al-Huniti N; Jadhav P; Wang Y; Byon W
    J Clin Pharmacol; 2015 Aug; 55(8):875-87. PubMed ID: 26148467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.
    Bujkiewicz S; Jones HE; Lai MC; Cooper NJ; Hawkins N; Squires H; Abrams KR; Spiegelhalter DJ; Sutton AJ
    Value Health; 2011; 14(5):768-76. PubMed ID: 21839417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches.
    Philipp M; Buatois S; Retout S; Mentré F
    J Pharmacokinet Pharmacodyn; 2024 Apr; ():. PubMed ID: 38594569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of machine learning methods for covariate data imputation in pharmacometrics.
    Bräm DS; Nahum U; Atkinson A; Koch G; Pfister M
    CPT Pharmacometrics Syst Pharmacol; 2022 Dec; 11(12):1638-1648. PubMed ID: 36346135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient and relevant stepwise covariate model building for pharmacometrics.
    Svensson RJ; Jonsson EN
    CPT Pharmacometrics Syst Pharmacol; 2022 Sep; 11(9):1210-1222. PubMed ID: 35851587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.